Although CDKN2A is the most frequent high-risk melanoma susceptibility gene, the underlying genetic factors for most melanoma-prone families remain unknown. Using whole-exome sequencing, we identified a rare variant that arose as a founder mutation in the telomere shelterin gene POT1 (chromosome 7, g.124493086C>T; p.Ser270Asn) in five unrelated melanomaprone families from Romagna, Italy. Carriers of this variant had increased telomere lengths and numbers of fragile telomeres, suggesting that this variant perturbs telomere maintenance. Two additional rare POT1 variants were identified in all cases sequenced in two separate Italian families, one variant per family, yielding a frequency for POT1 variants comparable to that for CDKN2A mutations in this population. These variants were not found in public databases or in 2,038 genotyped Italian controls. We also identified two rare recurrent POT1 variants in US and French familial melanoma cases. Our findings suggest that POT1 is a major susceptibility gene for familial melanoma in several populations.
Although CDKN2A is the most frequent high-risk melanoma susceptibility gene, the underlying genetic factors for most melanoma-prone families remain unknown. Using whole-exome sequencing, we identified a rare variant that arose as a founder mutation in the telomere shelterin gene POT1 (chromosome 7, g.124493086C>T; p.Ser270Asn) in five unrelated melanomaprone families from Romagna, Italy. Carriers of this variant had increased telomere lengths and numbers of fragile telomeres, suggesting that this variant perturbs telomere maintenance. Two additional rare POT1 variants were identified in all cases sequenced in two separate Italian families, one variant per family, yielding a frequency for POT1 variants comparable to that for CDKN2A mutations in this population. These variants were not found in public databases or in 2,038 genotyped Italian controls. We also identified two rare recurrent POT1 variants in US and French familial melanoma cases. Our findings suggest that POT1 is a major susceptibility gene for familial melanoma in several populations.
Approximately 10% of cutaneous malignant melanoma (CMM) cases occur in a familial setting 1 . Established high-penetrance melanoma susceptibility genes include CDKN2A on chromosome 9p21 and CDK4 on chromosome 12q14. Germline mutations of the CDKN2A gene have been described in approximately 20-40% of familial melanoma kindreds [2] [3] [4] [5] [6] , whereas mutations of CDK4 are quite rare, with only 17 published families worldwide 7, 8 . Recently, germline mutations in BAP1 (located at 3p21) were reported to predispose to melanocytic tumors, including uveal and cutaneous melanomas 9 . In addition, a germline mutation in the promoter of the telomerase reverse transcriptase gene (TERT), which encodes the catalytic subunit of telomerase, demonstrated cosegregation with disease in an informative melanoma-prone family 10 , suggesting that this gene may also be a rare high-penetrance CMM susceptibility gene. Together, these genes account for melanoma susceptibility in a small proportion of melanoma-prone families.
To identify additional high-penetrance susceptibility genes for familial CMM, we performed whole-exome sequencing in 101 CMM Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma cases or obligate carriers (assuming dominant inheritance) in 56 unrelated melanomaprone families without CDKN2A or CDK4 mutations recruited from the Romagna area in Italy. After filtering out common and non-segregating variants (Online Methods), the cosegregating rare variant that was present at the highest frequency in multiple families was a missense rare variant in the protection of telomeres 1 gene (POT1; g.124493086C>T; p.Ser270Asn, NP_056265); this variant was observed in all CMM cases or obligate carriers (n = 11) from 4 Italian families (F1-F4; Fig. 1 and Supplementary Table 1 ). We also detected this variant in one of two cases examined in a bilineal Italian family (F5; Fig. 1 ). One affected individual without the POT1 variant may have inherited the melanoma risk allele from the other side of the family, but the parental origin of this variant could not be determined. Targeted sequencing performed on all available subjects in the five families with the p.Ser270Asn variant confirmed its presence in CMM cases. The mode of transmission was consistent with autosomal dominant inheritance with incomplete penetrance. We performed genotyping for the variant in 2,038 Italian controls, and none carried the variant, resulting in a significantly different frequency of this variant in familial CMM cases compared to controls (P = 1.2 × 10 −11 after accounting for the relatedness among familial cases using a chromosome-based exact test; Online Methods). We further genotyped for this variant in 1,824 Italian CMM cases (Online Methods), and this variant was only found in a single sporadic melanoma case from Romagna ( Supplementary Table 1 ). This variant was not present in dbSNP, the 1000 Genomes Project (1,092 subjects), the National Heart, Lung, and Blood Institute (NHLBI) Grand Opportunity (GO) Exome Sequencing Project (ESP; including exomes from up to 4,300 subjects of European ancestry and 2,200 subjects of African-American ancestry), the National Cancer Institute (NCI) Division of Cancer Epidemiology and Genetics (DCEG) Cancer Sequencing Working Group database (290 and 200 individuals of European and Asian ancestry, respectively, from families with high risk of non-melanoma malignancies), an in-house McGill exome database (1,307 individuals of European ancestry with no cancers; M.L., unpublished data), and 878 CMM cases and 1,451 controls from Spain (Online Methods).
Because all subjects carrying the p.Ser270Asn variant were from Romagna, we verified the relatedness among p.Ser270Asn carriers using genome-wide SNP genotyping data (Online Methods). The kinship analysis did not detect cryptic relatedness across families at a threshold of 0.05 ( Supplementary Fig. 1) . Interestingly, the analysis identified a haplotype encompassing the POT1 region encoding p.Ser270Asn shared by all carriers, suggesting that the p.Ser270Asn variant was inherited from the same common ancestor. Using longrange phasing and modeling of the distribution of the lengths of the shared haplotypes encoding p.Ser270Asn, we estimated the age of the most recent common ancestor carrying the variant to be 9.5 (s.d. = 3.9) generations (Online Methods and Supplementary Fig. 2 ).
POT1 is a component of the telomeric shelterin complex that directly binds with high specificity to single-stranded telomeric repeats 11 . POT1 prevents inappropriate processing of exposed chromosome ends by DNA damage response pathways and regulates telomerase function, thereby having a critical role in maintaining telomere integrity and regulating telomere length 12 . POT1 contains two oligonucleotide/oligosaccharide-binding (OB) folds in the N terminus that bind to telomeric overhang. The first OB fold interacts with the first six nucleotides of the telomeric repeat, whereas the second OB fold binds and protects the 3′ single-stranded DNA (ssDNA) 13, 14 . Most reported POT1 somatic mutations 15 , including those found in chronic lymphocytic leukemia (CLL) 16 , affect the OB folds of POT1, indicating the importance of this region in human cancers. The previously unreported POT1 variant we identified, p.Ser270Asn, is located in the OB2 domain and appears to be in very close proximity to DNA-binding sites, on the basis of the crystal structure ( Fig. 2 and Supplementary Fig. 3 ) 13, 14 . The affected residue is highly conserved among vertebrates, and the variant was predicted to be deleterious by most computational programs we evaluated ( Fig. 2 and Supplementary Table 2 ).
Telomere length influences the requirement for telomere maintenance in human tumorigenesis 17 . To determine the impact of the p.Ser270Asn variant on telomere length and integrity, we compared telomere lengths in peripheral blood mononuclear cell (PBMC) DNA from CMM cases carrying the variant to those in age-matched CMM cases without the variant (controls) by telomere restriction fragment analysis ( Fig. 3a) . In agreement with previous reports on POT1 mutations 11, 16, 18 , we found that, in four unrelated carriers of the p.Ser270Asn variant with melanoma from whom we had obtained PBMCs, telomeres appeared to have increased in length and heterogeneity (evident by the presence of telomeric signals at higher and lower molecular weights), indicating that this variant perturbs telomere length maintenance. Quantitative telomere FISH (Q-FISH) analysis of metaphase spreads from ex vivo stimulated PBMCs further confirmed this observation ( Fig. 3b) . Compared to the age-matched control, the carrier of the p.Ser270Asn variant also had a significant increase in the average number of fragile telomeres (P < 0.0001; Fig. 3b ), the aberrant structures that are found in cells deficient in shelterin proteins and/or other proteins required for telomere replication [19] [20] [21] [22] . The p.Ser270Asn variant did not lead to chromosome breaks or fusions or to chromosomes or chromatids without detectable telomere signals. Moreover, it did not alter the length of 3′ overhangs or telomere sister chromatid exchanges, affect telomerase activity or induce a DNA damage response at telomeres indicated by the presence of telomere dysfunction-induced foci 23 (data not shown). These findings indicate that this rare variant perturbs telomere maintenance rather than causing direct DNA damage.
Exome sequencing analysis of Italian families also identified two other rare missense substitutions in POT1 (g.124464052C>G (p.Gln623His) and g.124503540C>T (p.Arg137His)) that were found in all cases sequenced in two additional families (F6 and F7, respectively; Supplementary Fig. 4 ). Both missense variants were absent from public databases and 3,489 genotyped controls (2,038 Italian and 1,451 Spanish individuals) and were predicted to Figure 1 Pedigrees of CMM-prone families with the POT1 variant g.124493086C>T encoding p.Ser270Asn. Filled symbols, CMM cases; square with a dot in the center, obligate variant carrier. "Y" indicates a variant carrier, and "N" indicates a non-carrier. Age (in years) is the age at diagnosis for CMM cases and the age at examination for unaffected family members. l e t t e r S npg l e t t e r S be deleterious by most algorithms (Supplementary Table 2 ). The p.Arg137His substitution affects the α helix in the OB1 domain, and the affected residue could have a key role in the structural integrity of the protein fold, indirectly influencing DNA binding when altered ( Fig. 2 and Supplementary Fig. 3 ). The p.Gln623His substitution affects the C terminus of POT1, which contains the TPP1-binding region. TPP1 (encoded by ACD) is another shelterin component and forms a heterodimer with POT1. POT1-TPP1 binding increases the affinity of POT1 for ssDNA by tenfold and enables the recruitment of telomerase to the overhang 24, 25 . Carriers of the p.Arg137His and p.Gln623His variants showed slightly but significantly increased telomere intensity signals (Supplementary Fig. 5 ) and telomere fragility ( Supplementary Fig. 6 ) in PBMCs compared to agematched controls (P < 0.01). We also evaluated copy number variations (CNVs) using exome data in these families (Online Methods) and observed no CNVs disrupting POT1.
To assess the overall genetic burden due to rare variants in the POT1 gene, we sequenced POT1 exons in 768 CMM cases and 768 controls collected from a multicentric melanoma case-control study from Italy (Online Methods), and we found that CMM cases showed a significant increase in burden for all rare variants (<1% in ESP and 1000 Genomes Project databases) compared to controls (31 carriers among cases and 15 carriers among controls; odds ratio (OR) = 2.1, 95% confidence interval (CI) = 1.1-4.2; P = 0.024, Fisher's exact test; Supplementary  Table 3 ). The difference was more significant when we restricted the analysis to exonic variants (16 carriers among cases and 3 carriers among controls; OR = 5.4, 95% CI = 1.5-29.2; P = 0.0021).
Subsequently, we used exome and targeted sequencing data obtained from familial CMM cases or sporadic cases with multiple primary melanomas (MPMs) in 3 other populations to further evaluate POT1 variants, including 68 families (139 cases) from the United States, 234 families (267 cases) and 157 MPMs from France and 3 families (10 cases) from Spain. We identified two recurrent germline missense variants (g.124499043C>T (p.Asp224Asn) and g.124469308C>G (p.Ala532Pro). The p.Asp224Asn variant was observed in 4 of 5 CMM cases from a US family ( Supplementary Fig. 4 and Supplementary  Table 1 ) and was found in only 1 of 6,500 subjects in ESP. This variant was also seen in a sporadic MPM case from Genoa, Italy. Like p.Ser270Asn, the p.Asp224Asn variant is located in the OB2 domain near DNA-binding sites (Fig. 2) . It was predicted to be deleterious by all evaluated variant prediction programs (Supplementary Table 2 ). The p.Ala532Pro variant was identified in a familial case (the only case in the family with DNA available) from a three-case family from France and in one French case with five melanomas and one basal cell carcinoma ( Supplementary Fig. 4 and Supplementary Table 1 ) and was not reported in ESP. The p.Ala532Pro variant was predicted to be damaging only by SIFT and PolyPhen-2, but the underlying mutation is located near a splice junction and is predicted to disturb normal splicing. Both p.Asp224Asn and p.Ala532Pro were technically validated, and neither was observed in the NCI DCEG or McGill in-house sequencing databases. Other rare POT1 variants identified in a single French familial or MPM case, all of which were confirmed by Sanger sequencing, are shown in Supplementary Table 4 . No rare POT1 variant cosegregating with disease was found in the Spanish families with CMM. npg l e t t e r S Because POT1 was reported to frequently undergo somatic mutations in CLL 16 , we also examined POT1 exome sequencing data obtained from 51 families with lymphoproliferative disorder (LPD) from the United States, including 171 LPD cases affected with CLL (n = 70), non-Hodgkin lymphoma (NHL; n = 16), Hodgkin lymphoma (n = 46) or Waldenström macroglobulinemia (n = 39) (Online Methods). No rare variants in POT1 were identified in the subjects with LPD.
In summary, we have identified POT1 as a susceptibility gene for familial melanoma in several populations. This finding is further supported by the discovery of POT1 variants in an independent study of melanoma-prone families from the UK and Australia 26 . In particular, we have identified germline rare variants of POT1 in Romagna, Italy, which showed a frequency comparable to that for CDKN2A mutations among melanoma-prone families in this population 27 . Together with the finding of TERT as a potential susceptibility gene in melanoma, our findings suggest that genes involved in telomere maintenance may have important roles in melanoma development. 
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Subjects and families. Italian families with CMM, US families with CMM, Spanish families with CMM and families with LPD are participants in institutional review board (IRB)-approved studies at NCI. Detailed descriptions of these studies have been reported previously 27, 31, 32 . In brief, the study of Italian families with CMM involving exome sequencing and POT1 sequencing or genotyping analyses included 101 CMM cases or obligate carriers and 198 unaffected individuals from 56 families negative for mutations in CDKN2A and CDK4 with 2-5 affected relatives who were recruited at the Dermatology Unit of Maurizio Bufalini Hospital in Cesena, Italy. The study of US families with CMM comprised 68 families negative for mutations in CDKN2A and CDK4 with 2-13 affected individuals who were ascertained through healthcare professionals or self-referral. All study participants were of European ancestry, and exome sequencing data were based on 139 CMM cases and 6 unaffected individuals. The families with LPD had two or more individuals affected with the same lymphoproliferative disorders, including CLL (n = 70), Waldenström macroglobulinemia (n = 39), Hodgkin lymphoma (n = 46) and NHL (n = 16), and were accrued through healthcare professionals or selfreferral. Exome sequencing was based on 171 affected individuals or obligate carriers and 5 unaffected individuals from 51 families. The French families with melanoma and sporadic cases with MPMs were recruited through a national network of French Dermatology and Oncogenetic clinics that constitute the French Familial Melanoma Study Group and the MELARISK collection. This study was approved by IRBs and has been described in detail previously 33 . The French data investigated in the present study included two sets of cases negative for mutations in CDKN2A and CDK4 that were sequenced independently. The first set contained 22 melanoma-prone families (45 cases) and 4 sporadic melanoma cases with MPMs with whole-exome sequencing conducted at McGill University. The second set included 212 families with melanoma (222 cases) and 153 MPMs, with POT1 sequenced at the Cancer Genomics Research (CGR) Laboratory at NCI. The Spanish family study included three families with seven affected and ten unaffected individuals, with whole-exome sequencing conducted at CGR. The 2,702 additional CMM cases included in POT1 genotyping were derived from a multicentric case-control study from Italy (n = 1,824) 34 and a case-control study from Valencia, Spain (n = 878) 35 . Unaffected individuals were controls from the two melanoma case-control studies (511 Italian, 1,451 Spanish) and 1,527 individuals without a personal history of cancer who were recruited as controls for Environment And Genetics in Lung cancer Etiology (EAGLE), a population-based case-control study of lung cancer conducted in Italy 36, 37 . A subset of these subjects, including 768 cases and 768 controls from Italy, was further sequenced for the coding region of POT1. Subjects were selected on the basis of their residence within or in the proximity of the Romagna area, where the rare variant encoding p.Ser270Asn that arose as a founder mutation was identified.
Of note, for all studies, familial CMM cases included individuals with single or multiple primary melanomas. Sporadic CMM cases with MPMs were counted separately and defined as MPMs to emphasize their potential genetic etiology.
All studies were approved by IRBs at NCI and/or local institutions. All subjects provided written informed consent.
Exome sequencing. Whole-exome sequencing for the Italian families with CMM, the US families with CMM, the Spanish families with CMM and the families with LPD was performed at CGR, DCEG, NCI. Detailed procedures are presented in the Supplementary Note and have been described previously 38 . Briefly, for each sample, 1.1 µg of genomic DNA extracted from blood was used for exome sequence capture, which was performed with SeqCap EZ Human Exome Library v2.0 or v3.0 (Roche NimbleGen). Pools of captured DNA then underwent paired-end sequencing using an Illumina HiSeq according to Illumina-provided protocols for 2 × 100-bp paired-end sequencing. Each exome was sequenced to high depth to achieve a minimum threshold of 80% of coding sequence covered with by least 15 reads, on the basis of the UCSC hg19 'known gene' transcripts. According to US NIH policy, the exome sequencing data used for discovery will be released to the database of Genotypes and Phenotypes (dbGaP).
Whole-exome sequencing of the French subjects was performed at the McGill University and Génome Québec Innovation Centre. Briefly, 3 µg of genomic DNA was used to perform exome capture with an Agilent SureSelect kit according to the manufacturer's instructions. We performed 100-bp pairedend sequencing on the Illumina HiSeq 2000 platform. We generated approximately 10 Gb of sequence for each sample such that at least 90% of the coding sequence was covered by at least ten reads.
Bioinformatic analysis. Details of the bioinformatic analysis pipeline are presented in the Supplementary Note and were previously described 38 .
Briefly, sequencing reads were aligned to the hg19 reference genome using Novoalign software version 2.07.14. Variant discovery and genotype calling of multi-allelic substitutions, insertions and deletions was performed on all individuals globally using the UnifiedGenotyper module from the Genome Analysis Toolkit (GATK) 39 with the minimum call quality parameter set to 30. An in-house NCI DCEG database containing variants present in 490 exomes (200 Asians and 290 individuals of European ancestry) from subjects in families with melanoma-unrelated cancer sequenced in parallel with our families with CMM and LPD was used as an additional control data set. We excluded variants that were observed more than once in the 1000 Genomes Project or the NHLBI ESP databases or were present more than once in our in-house exome database. We applied a dominant genetic model that required the variant to be present in all affected individuals within a family (including the single case sequenced in the family) or in all but 1 affected subject in families with >3 cases sequenced to reduce the impact of phenocopies or sequencing errors.
Variant annotation.
We used computational tools including PolyPhen-2, SIFT, Provean, MutationAssessor and MutationTaster to predict the potential impact of sequence variants on protein function. We also obtained conservation scores using GERP, PhastCons and PhyloP, as well as ProPhylER, to predict the impact of mutations on the basis of evolutionary constraint analyses.
Chromosome-based exact test. We developed a chromosome-based exact test to test the association between CMM and the p.Ser270Asn variant by appropriately accounting for the relatedness of familial CMM cases within the same families. The details of this approach are presented in the Supplementary Note. Briefly, we first conducted a kinship analysis, which did not identify cryptic relatedness across families using a kinship coefficient cutoff of 0.05. We then inferred identity by descent (IBD) at the region encoding p.Ser270Asn using SNP genotypes on the basis of exome sequencing data to identify independent chromosomes and the number of cases carrying each chromosome in each family at the locus. Under H 0 of no association, we randomly chose 5 chromosomes (from n = 4,229 total independent chromosomes), assigned them as p.Ser270Asn variant alleles and counted the number of cases carrying the variant allele (denoted M). The P value for the chromosome-based exact test is defined as the probability P(M ≥ M 0 |H 0 ), where M 0 = 11, which is the observed number of familial CMM cases carrying the variant allele encoding p.Ser270Asn (the obligate carrier was not included in this analysis).
Estimation of kinship coefficients across Italian families with CMM.
We estimated kinship coefficients to confirm the relationships of family members and to detect cryptic relatedness. In a first analysis, we merged the genotypes of Italian families with CMM and the EAGLE controls for 27,674 common autosomal SNPs overlapping between exomic sequencing (families with CMM) and the Illumina HumanHap550 BeadChip (EAGLE controls) and estimated the kinship coefficient using PLINK (v.1.07) 40 . In a second analysis, we genotyped the subjects carrying rare variants in POT1 using Illumina OmniExpress arrays with higher density to refine the estimates of kinship coefficients for these POT1 variant carriers using 306,684 common SNPs overlapping on the two Illumina genotyping platforms.
Estimation of the age of the most recent common ancestor carrying the variant encoding p.Ser270Asn. To investigate whether variants occurred independently or were inherited from a common ancestor, we performed haplotype analysis using BEAGLE 41 , combining genotype data for all carriers of p.Ser270Asn and EAGLE controls to improve haplotyping accuracy. npg in-gel hybridization as described 52 with minor modifications. Briefly, 1 µg of genomic DNA was resuspended in 15 µl of gp32 protection buffer and treated with 1 µg of RNase A and with or without Exo1 at 37 °C for 1 h. Samples were size fractionated on a 0.8% agarose gel in 0.5× TBE (Tris-borate-EDTA) at 8 V/cm. The gel was then dried at 50 °C for 1 h. The dried gel was rinsed with 2× SSC (saline-sodium citrate) and then hybridized with the high-specificity C-rich probe at 42 °C overnight. After two washes with 0.1% SDS-0.1× SSC for 15 min per wash, the gel was exposed to a phosphorimager screen, and signals were acquired by Storm860 PhosphorImager and quantified with ImageQuant software. The gel was then denatured in 0.5 M NaOH-1.5 M NaCl for 1 h at room temperature, neutralized in 1.5 M NaCl-0.5 M Tris-HCl (pH 8.0) for 15 min and hybridized to C-rich probe again at 42 °C overnight. After two washes with 0.1× SSC-0.1% SDS for 15 min per wash, the gel was exposed to a phosphorimager screen. Relative amounts of overhang were calculated by normalizing signals from the native gel to signals from the denatured gel. Experiments were repeated three times on each sample.
Cell lysate preparation and telomerase assays. S-100 extracts from PBMCs were prepared, and 5 µg and 1 µg of cell extract were assayed for the presence of telomerase activity using the telomere repeat amplification protocol (TRAP) assay as previously described 53 . RNase A treatment was used for negative controls.
